Zhi-Wen Zhang

Zhi-Wen Zhang

Auto-generated profile, based on publicly available information

Zhi-Wen Zhang

B Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Pharmaceutical Sciences , Jiangnan University , Wuxi , P. R. China

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2013 in Chinese Medical Journal
Verified
Journal Article
Open access
HZHaitao Zhang
Haitao Zhang
ZZZhi-Wen Zhang
Zhi-Wen Zhang
JXJing-Hui Xue
Jing-Hui Xue
HKHai-Bo Kong
Hai-Bo Kong
ALAi-Jun Liu
Ai-Jun Liu
DXDonggang Xu
Donggang Xu
Background: The RNA-binding motif protein 3 (RBM3), which is transcriptionally induced by low temperature and hypoxia, has recently been found to be upregulated in human tumors. However, its expression status in human astrocytoma is not well defined. This article focuses on the differential expression of RBM3 in human astrocytomas of different grades and normal brain tissues. Methods: RBM3 was detected in astrocytomas and normal brain tissues by quantitative real-time PCR, immunohistochemistry, and Western blotting. Analysis of variance was performed on the data from quantitative real-time PCR. The Fisher's exact test was used to analyze the immunohistochemistry results. A P-value of less than 0.05 indicates a statistically significant difference. Results: On one hand, the mRNA expression levels of three X-chromosome-related RBM genes (RBMX, RBM3, and RBM10) were detected by quantitative real-time PCR. The results showed that there were no significant differences in RBMX and RBM10 mRNA expression levels in human astrocytomas of different grades and normal brain tissues. However, RBM3 mRNA expression levels were elevated in high-grade (World Health Organization (WHO) Grade III-IV) astrocytomas versus low-grade (WHO Grade I-II) astrocytomas (5.06±0.66 vs. 1.60±0.58; P <0.05) or normal controls (5.06±0.66 vs. 1.03±0.22; P <0.05) as determined by quantitative real-time PCR analysis. On the other hand, immunohistochemistry showed an increased RBM3 labeling index in astrocytomas of different grades and normal brain tissues (positive staining rate: astrocytoma Grade IV, 92.9%; astrocytoma Grade III, 81.8%; astrocytoma Grade I-II, 50%; normal brain tissues, 37.5%; high-grade astrocytoma versus normal brain tissues, P <0.05; high-grade astrocytoma versus low-grade astrocytoma, P <0.05). The higher protein levels of RBM3 were also validated in high-grade astrocytomas and low-grade astrocytomas compared with normal brain tissues by Western blotting. Conclusions: These data suggest that the overexpression of RBM3 may serve as an important molecular mechanism underlying astrocytic carcinogenesis. Moreover, RBM3 may have proliferative and/or proto-oncogenic functions in human astrocytomas.

1 May 2018 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
YLYu-Xiao Liu
Yu-Xiao Liu
WLWen-Jia Liu
Wen-Jia Liu
HZHui-Ru Zhang
Hui-Ru Zhang
ZZZhi-Wen Zhang
Zhi-Wen Zhang
Delivery of bevacizumab by intracranial injection: assessment in glioma model Yu-Xiao Liu,1,* Wen-Jia Liu,2,* Hui-Ru Zhang,1,3 Zhi-Wen Zhang1 1Department of Neurosurgery, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, People’s Republic of China; 2Beijing Institute of Biotechnology, Beijing, People’s Republic of China; 3College of Biological Engineering, HeNan University of Technology, Beijing, People’s Republic of China *These authors contributed equally to this work Background: Many reports have indicated that the intravenous administration of bevacizumab produces a number of systemic side effects. Therefore, we investigated the therapeutic effects of intratumoral bevacizumab administration using a glioma animal model. Methods: The glioma cell lines U251 and U87 that carried luciferase were implanted into the brains of mice to develop glioma models. Glioma-bearing mice were treated with bevacizumab intravenously or intratumorally by Alzet micro-osmotic pumps, and the survival time of mice was monitored. Tumor volumes and location were observed by fluorescence imaging and histological analysis. Levels of microvessel marker, cancer stem cell marker as well as angiogenesis-, invasion-, and inflammation-related factors in tumors were examined by immunohistochemical staining. Results: Mice treated with intratumoral low-dose bevacizumab had smaller tumor volumes, longer survival time, lower microvessel density, and fewer cancer stem cells as compared with untreated and intravenously treated mice. Furthermore, expression levels of inflammation-related factors increased signifiwhereas that of angiogenesis- and invasion-related factors decreased in intratumorally treated animals, compared with intravenously treated mice. Conclusion: These results implied bevacizumab delivery by intratumoral injection via Alzet micro-osmotic pumps may be a more effective and safer protocol for treating gliomas. Keywords: bevacizumab, anti-angiogenic, glioma cell line, intratumoral delivery, fluorescence imaging

15 January 2008 in Biochemistry
Verified
Journal Article
Closed access
JZJie Zhu
Jie Zhu
CLChangsheng Lu
Changsheng Lu
MSMatthew Standland
Matthew Standland
ELEric Lai
Eric Lai
GMGabrielle N. Moreno
Gabrielle N. Moreno
ZZZhiwen Zhang
Zhiwen Zhang

1 March 2019 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
YLYu-Xiao Liu
Yu-Xiao Liu
Junnian ZhouJunnian Zhou
Junnian Zhou
KLKe-Hui Liu
Ke-Hui Liu
XFXiang-Pin Fu
Xiang-Pin Fu
ZZZhi-Wen Zhang
Zhi-Wen Zhang
WYWen Yue
Wen Yue
Purpose: A better understanding of the underlying molecular mechanisms in treatment failure of bevacizumab (BEV) for malignant glioma would contribute to overcome therapeutic resistance. Methods: Here, we used a quantitative proteomic method to identify molecular signatures of glioblastoma cell after BEV treatment by two-dimensional liquid chromatography-tandem mass spectrometry analysis and 6-plex iTRAQ quantification. Next, the function of cold-inducible RNA-binding protein (CIRP), one of the most significantly affected proteins by drug treatment, was evaluated in drug resistance of glioma cells by invasion assays and animal xenograft assays. Target molecules bound by CIRP were determined using RNA-binding protein immunoprecipitation and microarray analysis. Then, these mRNAs were identified by quantitative real-time PCR. Results: Eighty-seven proteins were identified with significant fold changes. The biological functional analysis indicated that most of the proteins were involved in the process of cellular signal transduction, cell adhesion, and protein transport. The expression of CIRP greatly decreased after BEV treatment, and ectopic expression of CIRP abolished cell migration in BEV-treated glioma cells. In addition, CIRP could bind mRNA of CXCL12 and inhibit BEV-induced increase of CXCL12 in glioma cells. Conclusion: These data suggested that CIRP may take part in BEV-induced migration of gliomas by binding of migration-relative RNAs.

12 March 2019 in Preparative Biochemistry & Biotechnology
Verified
Journal Article
Closed access
HXHongyu Xu
Hongyu Xu
ZZZhiwen Zhang
Zhiwen Zhang
HLHui Li
Hui Li
YYYujie Yan
Yujie Yan
JSJin-Song Shi
Jin-Song Shi
ZXZheng-Hong Xu
Zheng-Hong Xu
The metabolic mechanism of excessive exopolysaccharide (BMPS) synthesis by Bacillus mucilaginosus CGMCC5766 under CaCO3 addition was investigated. Under CaCO3 (5 g/L), the maximum BMPS concentration reached 28.4 g/L, which was 11.2 folds higher than that of the control. Proteomics was then used to analyze the proteins with substantial differences expressed by B. mucilaginosus with and without CaCO3 addition. The proteomic results revealed that the enzymes related to the central metabolic pathway, amino acid biosynthesis, and nucleotide metabolism were depressed. By contrast, the UDP–glucose pyrophosphorylase involved in BMPS biosynthesis was overexpressed and converted metabolic flux from the biomass accumulation to the biosynthesis of BMPS. This research provides a new and widened perspective into understanding the mechanism of BMPS biosynthesis and applying theoretical and practical significance for the improvement of BMPS production from B. mucilaginosus.

1 June 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
YLYu-Xiao Liu
Yu-Xiao Liu
JZJun-Nian Zhou
Jun-Nian Zhou
KLKe-Hui Liu
Ke-Hui Liu
XFXiang-Pin Fu
Xiang-Pin Fu
ZZZhi-Wen Zhang
Zhi-Wen Zhang
WYWen Yue
Wen Yue
CIRP Regulates BEV-Induced Cell Migration in Gliomas [Corrigendum]